报 告 人：Mohsen Ghanbari 博士
报告题目：Population-based omics data for complex disease studies
Mohsen Ghanbari is an assistant professor and the principal investigator of Molecular and Systems Epidemiology at Erasmus University Medical Center Rotterdam in the Netherlands. He is a multidisciplinary person with a background and experience in clinic, epidemiology and molecular biology. His research focuses on the identification and characterization of genetic determinants for complex disorders, including cardiovascular, neurodegenerative and liver diseases, by integrating (epi)genomics, transcriptomics, proteomics, and metabolomics data of epidemiological studies with state-of-the-art molecular and cellular model systems. He currently leads a research group of 1 postdoc, 5 PhD and 2 MSc students and also teaches in multiple courses on genetics of complex disorders offered by the Netherlands Institute of Health Sciences, Erasmus MC. As a PI (Principal Investigator) and member of the MT, he is coordinating various molecular and omics data in the Rotterdam Study (~15,000 elderly subjects) and the Erasmus Rucphen Family study (~3,000 subjects). He is also collaborating with several large international consortia across the world (e.g., CHARGE, BBMRI-NL) and involved in numerous collaborative projects focused on assessing the genetic basis of complex disorders.
Molecular and systems epidemiology are emerging innovative fields of research in which molecular, cellular, tissue, and organism levels of function are incorporated into computational models and epidemiologic studies to identify contributors to complex diseases at multiple levels as well as their interactions. This is made possible by recent rapid technological advances in high-throughput laboratory assays that measure biomarkers from biological samples. Although epidemiology has been proven valuable to identify associations between exposure and disease in populations, traditional epidemiology does so without obtaining information of the biological processes that underlie the associations. Molecular and systems epidemiology could enhance the measurement of exposure, effect, and susceptibility, and also give insight into complex biological mechanisms, and generate novel hypotheses about disease mechanisms. This knowledge will lead to the identification of early etiologic, diagnostic, and prognostic markers of disease, allow us to better target preventive strategies, and yield new therapeutics for disease.
The Rotterdam Study is a prospective cohort study (~15,000 subjects aged 45 years or over) ongoing since 1990 in the city of Rotterdam, in the Netherlands. The study targets cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, otolaryngological, locomotor, and respiratory diseases. The availability of high quality phenotypic and various omics data in the Rotterdam Study has created a great opportunity for genetic epidemiological studies to integrate various datasets and build a comprehensive and dynamic model of the molecular changes in diseases for biomarker and drug discovery.